文献速递消化道肿瘤与早癌肝病

DCLK1:人胆管癌中的推定干细胞标志物

DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma.
PubMed 文献 · Hepatology · 2021-01-01

该研究在体外评估DCLK1在肝内胆管癌(iCCA)和肝门部胆管癌(pCCA)中的表达与生物学功能。DCLK1在pCCA的LGR5+细胞和iCCA的CD133+细胞中基因与蛋白表达升高,其抑制剂LRRK2-IN-1呈剂量依赖性抗增殖并诱导凋亡。DCLK1仅见于肿瘤组织,血清DCLK1在iCCA和pCCA患者中高、在HCC和肝硬化患者中低、在健康对照中几乎检测不到。

要点

  • DCLK1在pCCA的LGR5+细胞和iCCA的CD133+细胞中基因与蛋白表达升高。
  • LRRK2-IN-1呈剂量依赖性抗增殖,并诱导凋亡、减少集落形成与集落大小。
  • DCLK1仅见于肿瘤组织而不见于健康组织,血清DCLK1可能成为早期CCA诊断的生物标志物。

核心结论

  • DCLK1标记iCCA的CD133+和pCCA的LGR5+特定CSC亚群,其抑制在原发性CCA细胞培养中发挥抗肿瘤效应。
  • 人血清DCLK1可能成为早期CCA诊断的血清生物标志物。

研究设计与样本

  • 研究为体外研究,对手术切除的人CCA标本进行酶消化、针对特定CSC标志物(LGR5、CD90、EpCAM、CD133、CD13)免疫分选并制备原代细胞培养。
  • 通过实时定量PCR、蛋白质印迹和免疫荧光分析CCA细胞培养中DCLK1表达。
  • 通过评估选择性DCLK1抑制剂LRRK2-IN-1对细胞增殖(MTS assay、细胞群体倍增时间)、凋亡和集落形成能力的影响进行功能研究。
  • 通过免疫组织化学和实时定量PCR原位研究DCLK1,通过酶联免疫吸附试验分析血清DCLK1浓度。

主要发现

  • 与未分选细胞相比,pCCA的LGR5+细胞和iCCA的CD133+细胞中DCLK1基因与蛋白表达升高。
  • LRRK2-IN-1呈剂量依赖性抗增殖效应。
  • 与未处理细胞相比,LRRK2-IN-1在iCCA和pCCA中均明显损害细胞增殖、诱导凋亡、降低集落形成能力和集落大小。
  • 原位分析证实DCLK1仅存在于肿瘤中,而不存在于健康组织。
  • 人血清中DCLK1在iCCA患者(高)、pCCA患者(高)、HCC患者(低)和肝硬化患者(低)中可检测到,在健康对照中几乎检测不到。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Cholangiocarcinoma (CCA) is a very aggressive cancer showing the presence of high cancer stem cells (CSCs). Doublecortin-like kinase1 (DCLK1) has been demonstrated as a CSC marker in different gastroenterological solid tumors. Our aim was to evaluate in vitro the expression and the biological function of DCLK1 in intrahepatic CCA (iCCA) and perihilar CCA (pCCA). APPROACH AND RESULTS: Specimens surgically resected of human CCA were enzymatically digested, submitted to immunosorting for specific CSC markers (LGR5 [leucine-rich repeat-containing G protein-coupled receptor], CD [clusters of differentiation] 90, EpCAM [epithelial cell adhesion molecule], CD133, and CD13), and primary cell cultures were prepared. DCLK1 expression was analyzed in CCA cell cultures by real-time quantitative PCR, western blot, and immunofluorescence. Functional studies have been performed by evaluating the effects of selective DCLK1 inhibitor (LRRK2-IN-1) on cell proliferation (MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay, cell population doubling time), apoptosis, and colony formation capacity. DCLK1 was investigated in situ by immunohistochemistry and real-time quantitative PCR. DCLK1 serum concentration was analyzed by enzyme-linked immunosorbent assay. We describe DCLK1 in CCA with an increased gene and protein DCLK1 expression in pCCALGR5+ and in iCCACD133+ cells compared with unsorted cells. LRRK2-IN-1 showed an anti-proliferative effect in a dose-dependent manner. LRRK2-IN-1 markedly impaired cell proliferation, induced apoptosis, and decreased colony formation capacity and colony size in both iCCA and pCCA compared with the untreated cells. In situ analysis confirmed that DCLK1 is present only in tumors, and not in healthy tissue. Interestingly, DCLK1 was detected in the human serum samples of patients with iCCA (high), pCCA (high), HCC (low), and cirrhosis (low), but it was almost undetectable in healthy controls. CONCLUSIONS: DCLK1 characterizes a specific CSC subpopulation of iCCACD133+ and pCCALGR5+ , and its inhibition exerts anti-neoplastic effects in primary CCA cell cultures. Human DCLK1 serum might represent a serum biomarker for the early CCA diagnosis.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Nevi L, Di Matteo S, Carpino G, et al. DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma. Hepatology. 2021. PMID: 32978808. doi:10.1002/hep.31571

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。